PARSIPPANY, N.J. (AP) - Biopharmaceutical company NPS Pharmaceuticals Inc. said Thursday it will sell its pilot manufacturing and laboratory facility in Canada for $4.3 million.
Also, the company said it is buying back a Salt Lake City facility for $20 million. It previously sold the facility in a sale-leaseback deal. The purchase is being made so the company can exit from its long-term lease. The building will be sold again as soon as practical, NPS said.
Last year, the company said it would close a facility in Canada, eliminate commercial sales and related field operations, end its agreement with Allergan to promote the drug Restasis for chronic dry eyes, and sublease the remaining 50 percent of its Salt Lake City facility. It also said it would cut staff by 53 percent to 230.